Detalhe da pesquisa
1.
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Dermatol Ther
; 35(2): e15231, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34820971
2.
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
J Am Acad Dermatol
; 83(1): 139-150, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213306
3.
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.
J Am Acad Dermatol
; 84(2): 513-517, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33122022
4.
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study.
J Am Acad Dermatol
; 82(3): 738-741, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306726
5.
Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.
Dermatol Ther (Heidelb)
; 9(3): 479-496, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31062222